Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rosuvastatin for Prevention of Deep Vein Thrombosis in Patients Undergoing Total Knee Replacement Arthroplasty: STOP DVT - A Prospective Randomized Controlled Trial
Brief Summary: Deep vein thrombosis (DVT)is devastating disease which influencing the mortality and morbidity of patients at-risk like those undergoing orthopedic surgery.

Recent publication suggested HMO-co-A reductase inhibitor (statin) may reduce the occurrence rate of venous thromboembolism in apparently healthy persons.

The pleiotropic property of statin like antioxidant, antithrombotic, anti-inflammatory may have effect on the positive results.

We are investigating whether rosuvastatin is associated with lower incidence of deep vein thrombosis (DVT) in patients undergoing total knee replacement arthroplasty(TKRA)who are at-high risk for developing DVT


Options:
A: Arm Label: Ezetimibe/simvastatin; Type: EXPERIMENTAL; Interventions: Drug: ezetimibe (+) simvastatin, Drug: atorvastatin 10 mg or simvastatin 20 mg | Arm Label: Doubling statin dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin 40 mg or atorvastatin 20 mg, Drug: atorvastatin 10 mg or simvastatin 20 mg | Arm Label: Rosuvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin, Drug: atorvastatin 10 mg or simvastatin 20 mg | Intervention Type: DRUG; Name: ezetimibe (+) simvastatin; Assigned to Arm(s): Ezetimibe/simvastatin | Intervention Type: DRUG; Name: simvastatin 40 mg or atorvastatin 20 mg; Assigned to Arm(s): Doubling statin dose | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin | Intervention Type: DRUG; Name: atorvastatin 10 mg or simvastatin 20 mg; Assigned to Arm(s): Doubling statin dose, Ezetimibe/simvastatin, Rosuvastatin
B: Arm Label: Combination Therapy; Type: EXPERIMENTAL; Interventions: Drug: Extended release niacin, Drug: Simvastatin | Arm Label: Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin | Intervention Type: DRUG; Name: Extended release niacin; Assigned to Arm(s): Combination Therapy | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Combination Therapy, Monotherapy
C: Arm Label: Experimental: Rosuvastatin + enoxaparin arm; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin 20mg/d for 14days | Arm Label: enoxaparin only; Type: ACTIVE_COMPARATOR; Interventions: Drug: enoxaparin only | Intervention Type: DRUG; Name: Rosuvastatin 20mg/d for 14days; Assigned to Arm(s): Experimental: Rosuvastatin + enoxaparin arm | Intervention Type: DRUG; Name: enoxaparin only; Assigned to Arm(s): enoxaparin only
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ezetimibe, Drug: Niaspan, Drug: Statin therapy, Behavioral: Standard care, Drug: Aspirin, Drug: Clopidogrel, Procedure: Percutaneous transluminal angioplasty (PTA) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Statin therapy, Behavioral: Standard care, Drug: Aspirin, Drug: Clopidogrel, Drug: Placebo Niaspan, Drug: Placebo Ezetimibe, Procedure: Percutaneous transluminal angioplasty (PTA) | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Niaspan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Statin therapy; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo Niaspan; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo Ezetimibe; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Percutaneous transluminal angioplasty (PTA); Assigned to Arm(s): 1, 2

Answer: C